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Neuron-specific antioxidant OXR1 extends
survival of a mouse model of amyotrophic
lateral sclerosis
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Amyotrophic lateral sclerosis is a devastating neurodegenerative disorder characterized by the progressive loss of spinal motor
neurons. While the aetiological mechanisms underlying the disease remain poorly understood, oxidative stress is a central
component of amyotrophic lateral sclerosis and contributes to motor neuron injury. Recently, oxidation resistance 1 (OXR1) has
emerged as a critical regulator of neuronal survival in response to oxidative stress, and is upregulated in the spinal cord of patients
with amyotrophic lateral sclerosis. Here, we tested the hypothesis that OXR1 is a key neuroprotective factor during amyotrophic
lateral sclerosis pathogenesis by crossing a new transgenic mouse line that overexpresses OXR1 in neurons with the SOD1G93A mouse
model of amyotrophic lateral sclerosis. Interestingly, we report that overexpression of OXR1 significantly extends survival, improves
motor deficits, and delays pathology in the spinal cord and in muscles of SOD1G93A mice. Furthermore, we find that overexpression
of OXR1 in neurons significantly delays non-cell-autonomous neuroinflammatory response, classic complement system activation,
and STAT3 activation through transcriptomic analysis of spinal cords of SOD1G93A mice. Taken together, these data identify OXR1
as the first neuron-specific antioxidant modulator of pathogenesis and disease progression in SOD1-mediated amyotrophic lateral
sclerosis, and suggest that OXR1 may serve as a novel target for future therapeutic strategies.
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Introduction
The neurodegenerative disorder amyotrophic lateral scler-
osis (ALS) is characterized by the progressive loss of upper
motor neurons in the cortex, and lower motor neurons in
the brainstem and the spinal cord, resulting in severe
muscle wasting and death due to respiratory failure
(Hardiman et al., 2011). While most ALS cases are spor-
adic, 10% of cases are familial with mutations in Cu/Zn
super oxide dismutase (SOD1) accounting for 20% of
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familial ALS cases (Ferraiuolo et al., 2011). Many studies
have identified oxidative stress as a feature of ALS patho-
genesis; for example, increased production of reactive
oxygen species (ROS) as well as oxidative damage to pro-
teins and lipids have been described in patients (Barber and
Shaw, 2010; D’Amico et al., 2013). Although the pathways
that instigate oxidative stress in ALS have not been eluci-
dated, it has been postulated that the close relationship of
SOD1 to mitochondrial function influences the generation
of reactive oxygen species (Valentine et al., 2005;
Vehvilainen et al., 2014). Indeed, patients with familial
SOD1 ALS show pathological features indicative of oxi-
dative stress, such as increased 3-nitrotyrosine levels, a
marker for oxidative damage in motor neurons (Beal
et al., 1997). Transgenic mice overexpressing human
SOD1G93A recapitulate many clinical features of ALS
patients, including defects in motor control, muscle denerv-
ation, and progressive degeneration of motor neurons
(Gurney et al., 1994). These SOD1G93A mice and other
ALS mouse models have been particularly valuable for
uncovering presymptomatic and early symptomatic patho-
genic pathways, including excitotoxicity, protein aggrega-
tion, and neuroinflammation (Ferraiuolo et al., 2011;
Swarup and Julien, 2011). Furthermore, SOD1 mouse
mutants have provided additional evidence that oxidative
stress and mitochondrial dysfunction are detrimental to
motor neuron survival in vivo (Valentine et al., 2005;
Barber and Shaw, 2010; Ferraiuolo et al., 2011; Swarup
and Julien, 2011; Pollari et al., 2014). However, despite
these new insights, the mechanisms by which ALS manifests
in patients remain unclear (Ferraiuolo et al., 2011; Swarup
and Julien, 2011).
Initially identified in a screen for genes that protect
against oxidative stress-induced damage, oxidation resist-
ance 1 (Oxr1) is a highly conserved gene expressed
throughout the CNS, and confers neuronal sensitivity to
oxidative stress-mediated apoptosis (Volkert et al., 2000;
Elliott and Volkert, 2004; Oliver et al., 2011).
Specifically, loss of Oxr1 in mice leads to severe cerebellar
ataxia, oxidative damage and cell death in cerebellar
granule neurons, and death before postnatal Day 26
(P26) (Oliver et al., 2011). Although OXR1 does not pos-
sess antioxidant scavenging properties, overexpression of
OXR1 renders neurons less susceptible to exogenous per-
oxide-induced apoptosis in vitro, suggesting that OXR1
regulates downstream pathways to protect neurons from
oxidative stress damage (Oliver et al., 2011).
Interestingly, intermediate isoforms of OXR1 are upregu-
lated in the spinal cord of ALS patients, and the full-length
isoform of OXR1 is upregulated in the presymptomatic
low-copy SOD1G93A ALS mice. These findings provide
the first line of evidence that overexpression of OXR1
may not only act as an early marker of oxidative stress,
but also have neuroprotective properties during neurode-
generative disease progression (Oliver et al., 2011).
Here, we demonstrate that overexpression of OXR1 in
neurons extends survival of SOD1G93A ALS mice and
delays spinal cord and muscle pathogenesis. Moreover,
OXR1 overexpression delays early SOD1G93A ALS-induced
alterations to the transcriptome, including the activation of
neuroinflammatory pathways in the spinal cord. Taken




All experiments were conducted in adherence to the guidelines
set forth by the UK Home Office regulations, and with the
approval of the University of Oxford Ethical Review Panel.
Tg(Prnp-Oxr1) mice, overexpressing an HA-tagged Oxr1
transgene driven by the mouse Prnp promoter, were generated
as previously described (Oliver et al., 2011) and maintained on
a C57BL/6 background. Transgenic SOD1G93A mice were ori-
ginally derived from the B6SJL-TgN(SOD1-G93A)1Gur
(Jackson Laboratory) strain and maintained on a C57BL/6
background. All mice studied were the progeny of a
SOD1G93A male and a Tg(Prnp-Oxr1) female. Mice from sev-
eral litters were required to generate each experimental cohort;
for quantitative transcriptional, pathological and immunohis-
tochemical analyses, all cohorts were sex-matched and a max-
imum of one animal per genotype was used from a single litter.
The bella mutant mouse, a progeny of an N-ethyl-N-nitro-
sourea-injected BALB/c male and a C3H/HeH female, has
been described previously (Oliver et al., 2011). The day of
vaginal plug and the day of birth were designated as E0.5
and P0, respectively.
Disease course analysis and behaviour
tests
Disease onset was retrospectively defined as the age when mice
reached maximum body weight as previously described (Weydt
et al., 2003; Boillee et al., 2006; Ludolph et al., 2007). Disease
end-stage was defined by the age when mice suffered from
functional paralysis of both hindlimbs; this phenotype has
recently been established experimentally as an earlier and
more humane but predictable and reproducible endpoint for
transgenic mouse models of ALS, limiting the duration of dis-
ease exposure (Solomon et al., 2011). Disease progression was
retrospectively defined as the number of days between disease
onset and disease end-stage for each mouse.
To test motor function, mice were placed on a grooved
plastic beam of a Rotarod device (Ugo Basile), which revolves
at a default 5 rpm, facing in an orientation opposite to the
rotation. The time latency to fall from the rod or complete
two rotations on the rod without an attempt to run was re-
corded; a single trial was carried out per day over 3 days in
total at each experimental time point and the recorded values
were averaged. To test for muscle strength, mice were held by
their tails, and gently placed on a grip strength device
(Chatillon), such that their forepaws gripped a metal mesh
bar attached to the apparatus. The mice were then gently
pulled across the metal mesh bar, and maximum force (g)
exerted before the mice released their grip was recorded.
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Three trials were recorded and the average force was calcu-
lated. All behavioural tests were conducted with the experi-
menter blind to genotypes.
Immunohistochemistry and histology
Mice were transcardially perfused with 0.9% saline containing
10 U/ml heparin, followed by 4% paraformaldehyde (PFA).
Brains and spinal cords were dissected and post-fixed over-
night in 4% PFA at 4C. Tissue was cryoprotected with
30% sucrose, mounted in O.C.T. (VWR) medium, and sec-
tioned at 15 mm on a cryostat (Leica). For muscle fibre type
staining, tissue samples were freshly dissected and frozen in
O.C.T. on isopentane in dry ice. Frozen transverse sections
were cut at 10 mm on a cryostat (Leica). Sections were blocked
in 5% bovine serum albumin (BSA) (Sigma)/PBS/0.3%
TritonTM X100 at room temperature for 1 h. Incubation
with primary antibodies was conducted overnight (16 h) at
4C or for 1 h at room temperature. For GFAP immunohisto-
chemistry, antibody incubation was carried out for 26 h at
4C. After washing with phosphate-buffered saline (PBS), sec-
tions were incubated with appropriate Alexa Fluor secondary
antibodies diluted 1:500 (Invitrogen) for 1 h at room tempera-
ture, washed in PBS and mounted in Histomount (National
Diagnostics) or Vetashield with DAPI (Vector Laboratories).
The following primary antibodies and dilutions were used:
rat anti-CD68 (1:400, Millipore Bioscience Research
Reagents); rabbit anti-GFAP (1:500, ab7260, Abcam); rabbit
anti-HA (1:100, Sigma); rabbit anti-HO-1 (1:300, Abcam);
mouse anti-MYHC1 (1:200, B8-F8, German Collection of
Microorganisms and Cell Cultures); mouse anti-MYHC2A
(1:200, SC-71, German Collection of Microorganisms and
Cell Cultures); mouse IgM anti-MYHC2B (1:100, BF-F3,
German Collection of Microorganisms and Cell Cultures);
and mouse anti-NeuN (1:500, Millipore).
For neuromuscular junction staining, fresh dissected muscles
were teased apart, and placed in 10% foetal calf serum in PBS/
0.2 TritonTM X-100 with an appropriate dilution of Alexa
Fluor 488 conjugated -bungarotoxin (Invitrogen) overnight
at 4C. The teased muscle samples were subsequently washed
in PBS three times, before being further teased apart, placed on
a slide, and mounted using Histomount.
For motor neuron counts, all large ventral horn motor neu-
rons on eight matched Nissl-stained 15-mm sections of lumbar
spinal cord segments (L1-L6) were counted and averaged per
section. For quantitative immunohistochemistry, six matched
15-mm sections of lumbar spinal cord segments (L1-L6) per
animal were stained and 0.2 mm2 regions of each anterior
horn were acquired using an AxioCam HR digital camera
(Zeiss) and quantified for total signal intensity using ImageJ
software. For each antibody, all slides were processed in par-
allel. All quantification was conducted with the experimenter
blind to the genotypes.
Muscle histopathology
For haematoxylin and eosin stain, fresh muscle sections were
placed in haematoxylin for an appropriate time, no longer
than 15 min, and briefly washed in distilled water. Sections
were subsequently bled in 70% ethanol/0.1% hydrochloric
acid for 10 s, and washed in distilled water. The sections
were then placed in eosin for 2 min, washed in distilled
water, dehydrated and then mounted using Histomount.
For muscle atrophy measurements, images were acquired
using an AxioCam HR digital camera (Zeiss) and the area
of muscle in atrophy and total muscle area were obtained
using AxioVision software (Zeiss).
For succinic dehydrogenase staining, fresh muscle sections
were incubated in 0.05 M phosphate buffer/0.05 M sodium
succinate/0.05% nitro blue tetrazolium chloride for 30 min at
37C, and subsequently rinsed in PBS. Sections were then fixed
in 4% PFA for 5 min and rinsed in 15% ethanol before being
mounted using Histomount. All quantification was conducted
with the experimenter blind to the genotypes.
Immunoprecipitation and
immunoblotting
Tissue extracts were prepared using appropriate amounts of
immunoprecipitation buffer (50 mM Tris-Cl, pH. 7.5,
150 mM NaCl, 1% CHAPS) for immunoprecipitation, or
RIPA buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.1%
SDS, 1% sodium deoxycholate, 1% NP-40) for immunoblot-
ting. Protein concentrations were quantified using BCA assays
(Pierce Thermo Scientific) for equal loading. For immunopre-
cipitation, tissue extracts were incubated with Sepharose
G-beads (Sigma) for 1 h at 4C, and after spinning down,
the supernatant was removed and incubated with an appropri-
ate amount of antibody for 2 h at 4C. Appropriate amounts
of Sepharose G-beads were added to the tissue extract and
antibody concoction for another hour at 4C. The Sepharose
G-beads bound to the antibody were then washed three times
with immunoprecipitation buffer. After adding 2 Laemmli
sample buffer, protein and immunoprecipitation samples
were boiled for 5 min at 100C, separated by 12% SDS-
PAGE, and transferred to PVDF membranes (Amersham).
Membranes were subsequently blocked with 5% skimmed
milk powder in PBS/2% Tween-20 (PBST) for 1 h at room
temperature, before incubation with appropriate primary anti-
body diluted in milk/PBST for either 1 h at room temperature
or overnight at 4C. After washing with PBST, membranes
were incubated with the appropriate HRP-conjugated second-
ary antibodies (1:10 000, Amersham), and blots were de-
veloped using ECL reagents (Amersham). Quantifications
were carried out by calculating expression relative to the load-
ing control using ImageJ software. For immunoblotting in
Supplementary Fig. 1B and C, blots were processed using
ImageQuant Las 4000 (GE Healthcare).
The following primary antibodies and dilutions were used:
rabbit anti-HA (1:10 000, Sigma); rabbit anti-HO-1 (1:1000
Enzo Life Sciences); rabbit anti-Oxr1 (1:1000); sheep anti-
SOD1 (1:1000, Calbiochem); rabbit anti-STAT3 (1:2000,
Cell Signaling); rabbit anti-p-STAT3 (1:1000, Cell Signaling);
and mouse anti-b-actin (1:6000, Sigma).
Microarray analysis
Total RNA was purified from tissue samples from four animals
of each genotype using the RNeasy Mini kit (Qiagen) and con-
taminating genomic DNA was removed using RNase-free DNase
I (Qiagen). The RNA integrity of all samples was assessed on a
BioAnalyzer; all samples had a RNA Integrity Number (RIN)
58 (Agilent Laboratories). Labelled sense single-stranded DNA
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for hybridization was generated from 200 ng of RNA with the
Affymetrix GeneChip WT PLUS Reagent Kit. The single-stranded
DNA was then fragmented and labelled using the Affymetrix WT
Terminal Labelling and Controls Kit, and the distribution of
fragment lengths was measured on the Agilent BioAnalyzer.
The labelled and fragmented single-stranded DNA was hybri-
dized to the Affymetrix GeneChip Mouse Gene 1.0 ST Array,
and then washed and stained using the Affymetrix Hybridization,
Wash, and Stain Kit, according to the manufacturer’s instruc-
tions. Chips were processed on an Affymetrix GeneChip
Fluidics Station 450 and Scanner 3000.
Microarray data were Robust Multi-array Average (RMA)
normalized using GeneSpring GX12.6 (Agilent). Differentially
expressed genes were identified using a false discovery rate
of 40.05 with a Benjamini and Hochberg multiple testing
correction (limma). The genes that were designated as ‘rescued’
fulfilled the following criteria: (i) genes that had a 41.3-fold
change and P50.05 between SOD1G93A samples and both
wild-type and Tg(Prnp-Oxr1) samples; and (ii) genes that
had a 51.2-fold change or P40.05 between SOD1G93A/
Tg(Prnp-Oxr1) samples and both wild-type and Tg(Prnp-
Oxr1) samples. The Ingenuity Pathways Analysis tool
(Ingenuity Systems, www.ingenuity.com) was used to gain
additional in silico functional information. The Functions
tool in Ingenuity relates genes of interest to known biological
functions and disease states and was used to detect the
most significant functional pathways in the ‘rescued’ genes.
Microarray data are available on request.
Quantitative real time PCR
Complementary DNA (cDNA) was synthesized with the
RevertAidTM First Strand cDNA Synthesis Kit (Fermentas),
using 1mg of total RNA for each reaction. Quantitative
RT-PCR reactions were subsequently carried out using SYBR
Green PCR master mix (Applied Biosystems) with primers and
cDNA added in optimized concentrations, using a StepOne
real-time PCR machine (Applied Biosystems) with cycling con-
ditions at 95C for 10 s, followed by 40 cycles of 55C for
15 s, 60C for 10 s. Gene amplification specificity was
verified by melting curve analyses. The primer sequences
used: C1qa (5’-CAACGTGGTTATCTTTGACAAGGT-3’
and 5’-GAAGTTGAAGTAATAGAAGCCGGG-3’); C1qb (5’-
CACCAACGCGAACGAGAACT-3’ and 5’-GGCCAGGCAC
CTTGCA-3’); C1qc (5’-CTACTTCGTCTACTACACATCGC
A-3’ and 5’-CACCATGCCATTGTAGTCATTGAC-3’); Cd52
(5’-TCCTCCTCTTCCTCACTATCATTCT-3’ and 5’-GGCA
CATTAAGGTATTGGCAAAGA-3’); Cd68 (5’-CTACATCA
GAGCCCGAGTAC -3’ and 5’-CTGGTAGGTTGATTGTCG








Oxr1 (5’-CAGTCGTGACTGGACAGGTTT-3’ and 5’-ATG
GGCTACATCTGGAGTCG-3’); Serpina3n (5’-CGAAACTG
TACCCTCTGACTGTAT-3’ and 5’-TTGGCTATCTTGGCT
ATAAAGGGG-3’); and Vim (5’-CGGAAAGTGGAATCCTT
GCAGG-3’ and 5’-AGCAGTGAGGTCAGGCTTGGAA-3’).
All values obtained were normalized with respect to mRNA
levels of Gapdh.
Statistical analysis
Results were analysed using Prism (GraphPad Software, Inc.)
with the statistical tests described in the text. Data are
presented as mean  SEM (standard error of mean), with n
indicating the number of independent biological replicates
used in each group for comparison.
Results
Tg(Prnp-Oxr1) transgenic mice over-
express OXR1 specifically in neurons
OXR1 is highly expressed in the CNS, and specifically in
neurons (Supplementary Fig. 1A) (Oliver et al., 2011). The
detection of OXR1 transcripts has also been reported out-
side of the CNS (Yang et al., 2014); however, by western
blot we show here that the brain and spinal cord express
the majority of the full-length OXR1 protein, with multiple
smaller isoforms present in the CNS and other organs
(Supplementary Fig. 1B). Thus, to study whether overex-
pression of OXR1 is neuroprotective in vivo, we generated
a transgenic mouse [Tg(Prnp-Oxr1)], in which the mouse
prion protein Prnp promoter drives overexpression of a
full-length mouse Oxr1 cDNA with a C-terminal HA-tag
(Borchelt et al., 1996). First we confirmed that expression
of HA-tagged OXR1 protein occurs in the spinal cord and
brain (Supplementary Fig. 1C); in addition, the Oxr1 trans-
gene is overexpressed as early as embryonic Day 13.5 (Fig.
1A and Supplementary Fig. 1D) and adult transgenic
Tg(Prnp-Oxr1) mice show a consistent 5-fold increase
in OXR1 protein expression compared to wild-type con-
trols in the spinal cord (Fig. 1B) and brain
(Supplementary Fig. 1E). Immunohistochemistry confirmed
the neuron-specific overexpression of OXR1; all Tg(Prnp-
Oxr1) neurons express cytoplasmic HA-tagged OXR1, and
no HA-stained cells are found in any NeuN-negative cell
populations in the brain or spinal cord (Fig. 1C and
Supplementary Fig. 1F).
OXR1 overexpression in neurons
extends survival in SOD1G93A mice
As we showed previously that OXR1 is upregulated in the
spinal cord of ALS patients (Oliver et al., 2011), we inves-
tigated whether overexpression of OXR1 from early devel-
opment can delay or prevent motor neuron degeneration by
crossing Tg(Prnp-Oxr1) mice with SOD1G93A mice
(Gurney et al., 1994). We analysed offspring from
this cross of all four genotypic combinations [wild-type
Tg(Prnp-Oxr1) ( + /OXR1), SOD1G93A (SOD/ + ), and
SOD/OXR1] for longitudinal behavioural and pathological
parameters. First, we confirmed that expression of the
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mutant SOD1G93A and Oxr1 transgenes were stable, irre-
spective of genotype, by immunoblotting and quantitative
RT-PCR (Supplementary Fig. 1G–J). Importantly, when we
compared wild-type mice with + /OXR1 progeny from the
same cross, we observed no overt muscle or neuromuscular
junction pathology (Supplementary Fig. 2A and B).
Consistent with these data, + /OXR1 mice do not perform
differently from wild-type controls on Rotarod or grip
strength tests (Supplementary Fig. 2C–F), and there is no
difference in survival rates (data not shown). Together,
these data confirm that no detrimental pathology occurs
under neuronal overexpression of OXR1 in vivo.
We also obtained survival rates in parallel for SOD/ +
and SOD/OXR1 mice using functional paralysis of both
hindlimbs to determine disease end-stage (Solomon et al.,
2011). Strikingly, in females, median survival is signifi-
cantly increased by 19% (P5 0.0001), from 149 days for
SOD/ + mice to 178 days for SOD/OXR1 animals (Fig.
2A). Similarly, in males, median survival is significantly
increased by 16.8% (P5 0.0001), from 149 days for
SOD/ + mice to 174 days for SOD/OXR1 mice (Fig. 2B).
We also objectively determined disease onset by assessing
peak weight (Ludolph et al., 2007); interestingly, disease
onset is significantly delayed by 15.6% (P50.0001) in fe-
males, from 106 days for SOD/ + mice to 122 days for
SOD/OXR1 animals, and by 11.0% (P50.05) in
males, from 110 days for SOD/ + mice to 122 days for
SOD/OXR1 animals (Fig. 2C and D). Furthermore, disease
progression is significantly extended by 24.2% (P5 0.05)
in females, from 43 days for SOD/ + mice to 53 days for
SOD/OXR1 animals, and by 32.2% (P5 0.05) in males,
from 37 days for SOD/ + mice to 48 days for SOD/OXR1
animals (Fig. 2E and F). These data demonstrate that
neuron-specific OXR1 overexpression improves survival in
SODG93A mice.
Neuronal OXR1 overexpression
improves motor function and spinal
cord pathology in SOD1G93A mice
Given the significant extension of lifespan in SOD/OXR1
mice, we next determined neuroprotective effects of OXR1
overexpression by comparing behaviour and pathology of
SOD/ + mice to that of SOD/OXR1 mice at the same
time-points during ALS disease pathogenesis, a method com-
monly used in studies examining genetic modifiers of SOD1-
mediated ALS (Boillee et al., 2006; Yamanaka et al., 2008;
Hetz et al., 2009; Van Hoecke et al., 2012; Frakes et al.,
2014; Seijffers et al., 2014). First, to examine whether neur-
onal overexpression of OXR1 improves motor dysfunction
in SOD1G93A mice, we measured Rotarod performance at
multiple time points. Interestingly, average latency to fall for
SOD/OXR1 mice is significantly longer than that of SOD/ +
mice at all time points, beginning as early as postnatal Day
60 for females (P5 0.05) and Day 90 for males (P5 0.001)
Figure 1 Tg(Prnp-Oxr1) mice overexpress OXR1 specifically in neurons. (A) Prnp-promoter drives overexpression of HA-tagged full-
length OXR1 as early as embryonic Day 13.5 (E13.5) in the spinal cord as shown by western blot in Tg(Prnp-Oxr1) mice ( + /OXR1) when
compared with wild-type ( + / + ). (B) Representative western blot showing a 5-fold increase in spinal cord expression of OXR1 (arrow) in + /
OXR1 mice when compared with wild-type. The same membrane was reprobed with anti-HA to show HA-tagged full-length OXR1 and anti-b-
actin as the loading control for quantification; values are mean  SEM (n = 3 per genotype; ***P5 0.001, two-tailed Student’s t-test). Sizes of the
bands correspond to those in (A). (C) Immunohistochemical staining for NeuN, a marker for neurons (arrows), and HA-tagged OXR1, in the
spinal cord, demonstrating that Prnp-promoter driven OXR1 overexpression in + /OXR1 mice is specific to neurons. Scale bar = 50 mm.
P1 = postnatal Day 1; WB = western blot.
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(Fig. 3A and B). We then quantified motor neuron survival
in the lumbar spinal cord at Days 90 and 135 to determine
whether the improved motor function in SOD/OXR1 mice is
a result of delayed neuropathology. Importantly, while no
significant differences in motor neuron survival were
observed between the four genotypes at Day 90, motor
neuron viability is significantly improved in SOD/OXR1
mice when compared to that of SOD/ + mice at Day 135
(P5 0.05), with motor neuron numbers in SOD/OXR1 mice
almost equivalent to wild-type or + /OXR1 animals (Fig.
3C–F). We previously showed that OXR1 protects against
oxidative stress-induced apoptosis (Oliver et al., 2011),
therefore we determined whether neuronal overexpression
of OXR1 reduces oxidative stress in spinal cord of SOD/ +
mice by immunoblotting for heme-oxygenase 1 (HMOX1,
previously known as HO-1), a marker of oxidative stress in
SOD1G93A mice (Ferrante et al., 1997). HMOX1 expression
is significantly induced in SOD/ + mice at Day 135 when
compared to wild-type and + /OXR1 controls (P5 0.01;
Fig. 3G), with this induction detected in neuronal cells of
the spinal cord (Fig. 3H). Importantly, HMOX1 induction
is significantly reduced in SOD/OXR1 animals when com-
pared to SOD/ + mice (P5 0.05; Fig. 3G). Together, these
results establish that OXR1 ameliorates motor function and
delays pathogenesis in the spinal cord of SOD1G93A mice.
Neuronal OXR1 overexpression
improves muscle function and delays
muscle pathology in SOD1G93A mice
As muscle dysfunction and atrophy are downstream conse-
quences of motor neuron loss in ALS patients and
SOD1G93A mice (Gurney et al., 1994; Abe et al., 1996),
we investigated whether overexpression of OXR1 in neu-
rons improves muscle pathology in SOD1G93A mice. To
measure muscle function, we analysed performance of
mice on a grip strength monitor, and found that SOD/
OXR1 mice have significantly improved muscle strength
when compared with SOD/ + animals (P5 0.05) from
Day 120 in both males and females (Fig. 4A–F). Given
gastrocnemius muscle atrophy has been noted in
SOD1G93A mice (Gurney et al., 1994), we first conducted
histological analysis of this muscle group. Gastrocnemius
muscle atrophy of SOD/OXR1 mice is significantly reduced
by 2-fold at Day 90 (P5 0.05) and 3-fold at Day 135
(P5 0.01), when compared to that of SOD/ + mice (Fig.
4G–I). Interestingly, we also found that abnormal gastro-
cnemius neuromuscular junction morphology in SOD/ +
mice is significantly reduced in SOD/OXR1 animals at
Day 90 (P5 0.05) (Supplementary Fig. 2G–I). Finally, pre-
vious studies reported that extensor digitorum longus
Figure 2 Neuronal overexpression of OXR1 extends lifespan of SOD1G93A mice. Kaplan-Meier log rank test for survival, showing
OXR1 overexpression increases median survival (A) from 149 days for SOD/ + females to 178 days for SOD/OXR1 females; and (B) from 149
days for SOD/ + males to 174 days for SOD/OXR1 males (n = 10–12 per sex per genotype). (A and B) Survival curves are significantly different
by Mantel-Cox test, P5 0.0001 (2 = 24.99) for males, and P5 0.0001 (2 = 22.05) for females. OXR1 overexpression delays disease onset,
defined by the age of maximum body weight, (C) from 106 days for SOD/ + females to 122 days for SOD/OXR1 females; and (D) from 110 days
for SOD/ + males to 122 days for SOD/OXR1 males. OXR1 overexpression slows disease progression, defined by time of disease onset to end-
stage, (E) from 43 days for SOD/ + females to 53 days for SOD/OXR1 females; and (F) from 37 days for SOD/ + males to 48 days for SOD/OXR1
males. (C–F) Values are mean  SEM (n = 9–16 per sex per genotype; *P5 0.05, **P5 0.01, ***P5 0.001; two-tailed Student’s test).
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muscles of SOD1G93A mice become more fatigue resistant
(Kieran et al., 2005), thus we examined muscle fibre-type
by immunohistochemical staining for type I, IIA and IIB
fibres. We found that EDL muscles of SOD/ + mice have
a significant decrease in type IIB fibres, and an increase in
type IIA fibres when compared to that of wild-type, + /
OXR1 or SOD/OXR1 animals (P5 0.01) (Fig. 4J and
Supplementary Fig. 2J). Corroborating these findings, stain-
ing for oxidative enzyme succinate dehydrogenase showed
a marked increase in dark-stained muscle fibres only in
EDL muscles of SOD/ + mice (Supplementary Fig. 2K).
These data demonstrate that overexpression of OXR1 in
neurons delays atrophy in gastrocnemius muscles, and ab-
normal changes in oxidative capacity in extensor digitorum
longus muscles of SOD1G93A mice.
Transcriptomics reveals that OXR1
overexpression in neurons delays
early gene expression changes in the
spinal cord of SOD1G93A mice
We then chose to investigate how OXR1 modulates patho-
genesis in SOD1G93A mice by performing microarray
Figure 3 Neuronal overexpression of OXR1 improves motor function and motor neuron survival in SOD1G93A mice. (A) SOD/
OXR1 females and (B) males have improved motor performance on the accelerating Rotarod when compared with SOD/ + females and males,
respectively. (A and B) Values are mean  SEM of motor performance (seconds, s) for mice still alive at each respective time point (n = 9–11 per
sex per genotype at Days 60–120 and n = 6–11 per sex per genotype at Days 135–165 due animals reaching end-stage; *P5 0.05, **P5 0.01,
***P5 0.001, Mann-Whitney U-tests). Representative images of Nissl-stained motor neurons in matching lumbar spinal cord cross-sections at
Day 90 (C) and Day 135 (E). Motor neuron survival counts in lumbar spinal cord cross-sections at Day 90 (D) and Day 135 (F); values are
mean  SEM (n = 3–4 per genotype; *P5 0.05, **P5 0.01; 1-way ANOVA, with Tukey’s post hoc tests). Scale bar = 100 mm. (G) Western blot
showing reduced induction of HMOX1 (HO-1, arrow) in SOD/OXR1 mice. The same membrane was re-probed with anti-b-actin as the loading
control for quantification; values are mean  SEM (n = 3 per genotype; *P5 0.05, **P5 0.01; one-way ANOVA, with Tukey’s post hoc tests). (H)
Immunohistochemical staining for HMOX1 and NeuN in the spinal cord demonstrating HMOX1 expression in neurons. Scale bar = 30 mm.
P90 = postnatal Day 90; P135 = postnatal Day 135; WB = western blot.
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transcriptome analysis on spinal cord tissue at Day 90 prior
to significant motor neuron loss. We purified RNA from
the lumbar region of littermate mice of all four genotypic
combinations to correspond with the same region used for
quantifying motor neuron survival and to ensure that
potentially important non-cell autonomous expression
changes could be identified (Fig. 3C and E). Comparing
the SOD/ + expression profile to that of wild-type and + /
OXR1 mice identified 65 differentially expressed genes
(Supplementary Table 1), including dysregulation of Atf3,
C1qa, Ctss, HexB, and Sprr1a, confirming results from
previous studies of the SODG93A spinal cord (Olsen et al.,
2001; Yoshihara et al., 2002; Perrin et al., 2005; Ferraiuolo
et al., 2007; Lobsiger et al., 2007; Chen et al., 2010;
Lincecum et al., 2010). Importantly, we also observed no
significant gene expression changes between wild-type and
+ /OXR1 mice apart from the expected Oxr1 overexpres-
sion from the Oxr1 transgene itself (Supplementary Table
2); this further confirms that presence of the Oxr1 trans-
gene does not have a detrimental effect on spinal cord
Figure 4 Neuronal overexpression of OXR1 delays muscle pathology in SOD1G93A ALS mice. (A–C) SOD/OXR1 females show
significantly improved muscle strength (g) on a grip strength test when compared with SOD/ + females at (C) Day 120 (P120), but not at (A) Day
60 (P60) or (B) Day 90 (P90). (D–F) SOD/OXR1 males show significantly improved muscle strength (g) on grip strength test when compared with
SOD/ + males at (F) Day 120, but not at (D) Day 60 or (E) Day 90. (A–F) Values are mean  SEM (n = 12–24 per genotype; ***P5 0.001, Mann-
Whitney U tests). (G and H) Gastrocnemius muscle atrophy is decreased in SOD/OXR1 mice compared with SOD/ + mice at (G) Day 90 and
(H) Day 135. (G and H) Values are mean  SEM (n = 3–6 per genotype; *P5 0.05, **P5 0.01, two-tailed Student’s test). (I) Representative
images of haemotoxylin and eosin (H&E) stained gastrocnemius muscle fibres at Day 135. (J) Extensor digitorum longus (EDL) muscles of SOD/ +
mice have increased type IIA and decreased type IIB fibres, when compared to wild-type ( + / + ), + /OXR1, and SOD/OXR1 mice at Day 90.
Values are mean  SEM (n = 4–6 per genotype; **P5 0.01, two-way ANOVA, followed by Bonferroni post hoc tests).
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function or transcriptional regulation, in-line with behav-
ioural and pathological data described above
(Supplementary Figs 1 and 2).
More importantly, we identified 63 ‘rescued’ genes in
SOD/OXR1 mice; defined as those genes that are signifi-
cantly altered by 41.3-fold in the SOD/ + spinal cord,
but not significantly changed or altered by 51.2-fold in
SOD/OXR1 tissue (Fig. 5A and B, and Supplementary
Table 3). Using pathway analysis of these genes, we
found that overexpression of OXR1 influences a range of
important pathogenic mechanisms that have been previ-
ously found to be deregulated in ALS (Fig. 5C) (Olsen
et al., 2001; Yoshihara et al., 2002; Perrin et al., 2005;
Ferraiuolo et al., 2007; Chen et al., 2010; Lincecum
et al., 2010). Furthermore, selected genetic modifiers in
these particular pathways can extend survival of mutant
SOD1 mice (Turner and Talbot, 2008; Riboldi et al.,
2011). Together, these data suggest that OXR1 functions
upstream of diverse biological functions during ALS patho-




response in SOD1G93A mice
Because immune cell trafficking was identified as a key
pathogenic pathway delayed by OXR1 overexpression
(Fig. 5C), and the fly orthologue of OXR1 has been impli-
cated in regulating innate immunity (Wang et al., 2012),
we chose to further validate four markers of macrophages
or immune activation, Ctss, Mpeg1, Lyz2, and Cd52
(Olsen et al., 2001; Ferraiuolo et al., 2007)
(Supplementary Table 3). We examined expression profiles
of these genes in independent samples of spinal cord of
Days 60, 90 and 135 to assess the extent and timing of
candidate gene deregulation both prior to and during dis-
ease progression. Quantitative RT-PCR confirmed that Ctss
and Lyz2 are significantly upregulated in the spinal cord of
SOD/ + mice but not in that of SOD/OXR1 animals at
Days 90 and 135 (Fig. 6A–C and Supplementary Fig.
3A–C). Importantly, the same pattern of ‘rescued’ expres-
sion for both genes was observed at Day 60, suggesting
that OXR1 influences immune pathways prior to disease
onset (Fig. 6A and Supplementary Fig. 3A). Induction of
Cd52 and Mpeg1 is observed in the SOD/ + spinal cord,
but not in the SOD/OXR1 spinal cord at Days 90 and 135
(Fig. 6D–F and Supplementary Fig. 3D–F). At Day 135,
this effect is more pronounced; for example, relative expres-
sion of Ctss is increased in the SOD/ + and SOD/OXR1
spinal cord by 7-fold and 3-fold, respectively (Fig. 6C).
To further investigate this phenomenon, we conducted
quantitative immunohistochemical staining at Days 60, 90
and 135 for GFAP, a marker for astrogliosis (Fig. 6G)
(Lincecum et al., 2010; Papadeas et al., 2011). Levels of
GFAP-positively stained activated astrocytes are not
significantly different at Day 60 across all four genotypes,
but by Day 90 a significant 2-fold relative increase in the
SOD/ + spinal cord was observed (Fig. 6H and I). At Day
135, while relative GFAP-staining is increased by 9-fold
in SOD/ + mice compared to wild-type and + /OXR1 ani-
mals, expression is significantly reduced in SOD/OXR1 ani-
mals close to the levels observed in controls (Fig. 6J). We
also investigated the role of OXR1 overexpression on
microgliosis in SODG93A mice, as suggested by the presence
of Cd68 as one of the genes ‘rescued’ in SOD/OXR1 ani-
mals (Supplementary Table 3) (Lincecum et al., 2010;
Papadeas et al., 2011). First we validated that Cd68 was
significantly upregulated in the spinal cord of SOD/ + mice,
but not in SOD/OXR1 animals at Day 90 by quantitative
PCR (Fig. 6K and L). Furthermore, at Day 135, Cd68 was
induced by 6-fold in SOD/ + mice but was markedly and
significantly reduced in SOD/OXR1 animals (Fig. 6M). By
quantitative immunohistochemistry, no differences in the
levels of CD68-postive activated microglia in the spinal
cord were observed between genotypes at Days 60 and
90 (data not shown), but we confirmed that SOD/OXR1
mice have significantly decreased levels of CD68-postive
microglia when compared to SOD/ + animals at Day 135
(Fig. 6N and O). Finally, we confirmed that these findings
are due to neuron-specific overexpression of OXR1 by
demonstrating that overexpression of OXR1 does not co-
localize with GFAP-positive activated astrocytes or CD68
activated microglia in SOD/OXR1 mice (Supplementary
Fig. 4A and B).
To better understand mechanisms by which OXR1 delays
inflammation in the SOD1G93A spinal cord, we further exam-
ined activation pathways upstream of the immune response.
In particular, the complement pathway was identified by
microarray pathway analysis as being significantly activated
in SOD/ + but not SOD/OXR1 mice at Day 90
(Supplementary Table 4); due, in part, to genes such as
those encoding complement-activating C1q proteins
(Lobsiger et al., 2013) being identified as ‘rescued’ by
neuronal OXR1 overexpression (Supplementary Table 3).
We confirmed upregulation of C1qa, C1qb and C1qc
in SOD/ + mice is significantly less pronounced in
SOD/OXR1 mice at Days 90 and 135 by quantitative RT-
PCR (Fig. 7A–C and Supplementary Fig. 3G–L), suggesting
that OXR1 functions upstream of classic complement path-
way activation. Furthermore, STAT3, a key regulator of in-
flammatory response, was identified from pathway analysis as
functioning upstream of the ‘rescued’ genes observed at Day
90 (Supplementary Table 5). Interestingly, STAT3 is activated
in ALS patients and SOD1G93A mice (Shibata et al., 2009,
2010), thus we determined whether OXR1 overexpression
alters levels of phosphorylated STAT3 (p-STAT3) at Day 90
by immunoblotting. Upregulated p-STAT3 in the spinal cord
of SOD/ + mice is markedly reduced to wild-type levels under
neuronal overexpression of OXR1 (Fig. 7D). Therefore, we
next examined expression of two genes, Vim and Serpina3n,
which were identified as ‘rescued’ in the Day 90 microarray,
and are downstream targets of the activated STAT3 pathway
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(Supplementary Tables 3 and 5). At Days 90 and 135, Vim
and Serpina3n are significantly increased in SOD/ + mice,
but this upregulation is significantly reduced in SOD/OXR1
mice (Fig. 7E–G and Supplementary Fig. 3M–O), further sup-
porting OXR1 function upstream of the STAT3-activated
immune response pathway. Together, these data demonstrate
that neuronal OXR1 overexpression is sufficient to decrease
pathological neuroinflammation through regulating activation
of multiple pathways in the spinal cord of SOD1G93A mice.
Discussion
Here, we established OXR1 as a novel genetic modifier
of ALS, and found that neuron-specific overexpression
of OXR1 extends lifespan and delays ALS disease
pathogenesis. OXR1 improves motor function, increases
motor neuron survival, and protects against oxidative
stress in the SOD1G93A spinal cord (Fig. 3). We also demon-
strated that OXR1 increases muscle strength, and delays
gastrocnemius muscle atrophy and fatigue-resistant EDL
muscle fibre changes (Fig. 4). OXR1 is one of only three
known proteins that, when overexpressed in neurons,
delays motor dysfunction and improves muscle pathology
in mutant SOD1G93A mice (Figs 2 and 3) (Storkebaum
et al., 2005; Seijffers et al., 2014). Importantly, OXR1
is the first antioxidant that has been shown to in-
crease survival of SOD1G93A mice through specific
overexpression in neurons (Turner and Talbot, 2008;
Riboldi et al., 2011).
In this study, we conducted microarray analysis to un-
cover pathways by which OXR1 confers its neuroprotective
Figure 5 Neuronal OXR1 overexpression delays early transcriptome changes in SOD1G93A spinal cord. (A) Venn diagram illus-
trates the common expression overlap from microarray analysis to identify 63 ‘rescued’ genes; those that are significantly changed (P4 0.05) by
41.3-fold in SOD/ + spinal cord, but not significantly changed (P4 0.05) or by 51.2-fold in the SOD/OXR1 spinal cord at Day 90 after
correcting for multiple comparisons. (B) Heat map of normalized signal intensity values for all genes identified as ‘rescued’ by neuronal OXR1
overexpression at Day 90. (C) Pathway analysis demonstrates that neuronal OXR1 overexpression delays SOD1G93A-induced changes in diverse
molecular pathways at Day 90. Significance of identified pathways is presented as a –log(P-value), where P4 0.05 is –log(P-value)5 1.3.
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benefits at Day 90, a time point that we observed is
prior to significant motor neuron loss in SOD/ + mice
(Figs 3 and 6). We found that overexpression of OXR1
in neurons significantly delays dysregulation of genes that
are involved in diverse molecular functions altered in ALS
(Olsen et al., 2001; Yoshihara et al., 2002; Chen et al.,
2010), including a striking delay in the inflammatory re-
sponse (Figs 5–7). Neuroinflammation has been inextric-
ably linked to ALS disease progression, and in particular,
activated microglia and astrocytes substantially contribute
to motor neuron death (Ilieva et al., 2009; Ferraiuolo et al.,
2011; Bowerman et al., 2013). Specific deletion of mutant
SOD1 from either astrocytes or microglia significantly
slows disease progression in SOD1G93A mice, while mono-
clonal antibody treatment against CD-40L, a T cell surface
ligand that activates the immune response, or inhibiting
NF-B activation in microglia significantly extends survival
in SOD1G93A mice (Boillee et al., 2006; Yamanaka et al.,
2008; Lincecum et al., 2010; Frakes et al., 2014).
Moreover, transplantation of SOD1G93A glial-restricted
progenitors into spinal cord of wild-type rats induces
astrogliosis and microgliosis, motor dysfunction, and
motor neuron death, demonstrating non-cell autonomous
toxicity in ALS (Papadeas et al., 2011).
Here, we showed that OXR1 influences genes involved in
immune activation, including Ctss and Lyz2, as early as
Day 60, a time point prior to disease onset (Fig. 6 and
Supplementary Fig. 3). This supports the hypothesis that
the delay in neuroinflammation observed in SOD/OXR1
compared to SOD/ + animals is not simply due to a delay
in spinal motor neuron death. Indeed, increased motor
neuron survival does not always correlate with delayed
neuroinflammation. For example, either a 50% decrease
in expression of the ephrin receptor EphA4, or neuron-
specific deletion of the transcription factor Xbp1, decreases
motor neuron apoptosis in SOD1 mutant mice without
Figure 6 Neuronal OXR1 overexpression decreases neuroinflammation in SOD1G93A spinal cord. (A–C) SOD1G93A-induced
expression of Ctss, a marker of neuroinflammation, in the spinal cord is reduced in SOD/OXR1 mice at Days 60, 90 and 135 as shown by
quantitative RT-PCR. (D–F) Induced expression of Mpeg1, a macrophage marker, in the SOD1G93A spinal cord is reduced by overexpression of
OXR1 at Day 90 (P90), and Day 135 (P135) as shown by quantitative RT-PCR. (G–J) Immunohistochemical staining for GFAP on matching
sections of lumbar spinal cord, showing significantly decreased astrogliosis in SOD/OXR1 mice when compared to SOD/ + mice at Days 90 and
135. (K–M) Induced expression of Cd68, a marker of microgliosis, in the SODG93A spinal cord is significantly reduced in SOD/OXR1 mice at Days
90 and 135 as shown by quantitative RT-PCR. (N–O) Immunohistochemical staining for CD68 on matching sections of lumbar spinal cord shows
decreased microgliosis in SOD/OXR1 mice when compared to SOD/ + mice at Day 135. Values are mean  SEM [n = 3–5 per genotype (A–F and
K–M), n = 3 per genotype (G–J and N–O); *P5 0.05, **P5 0.01, ***P5 0.001, one-way ANOVA with Tukey’s post hoc tests]. Scale
bars = 100 mm.
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altering neuroinflammation (Hetz et al., 2009; Van Hoecke
et al., 2012). Therefore our finding that overexpression of
OXR1 modulates the immune response prior to significant
motor neuron loss during ALS pathogenesis is particularly
important.
Furthermore, we demonstrated that OXR1 functions up-
stream of multiple pathways that activate the immune
system, including the complement system and STAT3
pathway. In particular, overexpression of OXR1 delays in-
duction of C1qa/b/c, encoding for C1q-/b-/-chains, which
initiates the classic complement pathway responsible for
mediating the immune response (Fig. 7). Induction of C1q
in motor neurons and the global complement pathway in
the spinal cord of mutant SOD1 mice has been reported in
many studies (Olsen et al., 2001; Perrin et al., 2005;
Bonifati and Kishore, 2007; Ferraiuolo et al., 2007;
Figure 7 Neuronal OXR1 overexpression delays activation of neuroinflammatory pathways in the spinal cord of SOD1G93A
ALS mice. (A–C) SOD1G93A induced activation of genes C1qa, which encodes C1q  component, is reduced in SOD/OXR1 mice at Days 90
(P90) and 135 (P135). (D) Immunoprecipitation showing induced expression of phosphorylated-STAT3 in the SOD1G93A spinal cord is reduced by
overexpression of OXR1 at Day 90. Quantification of p-STAT3, and values are mean  SEM (n = 5 per genotype; *P5 0.05, **P5 0.01, one-way
ANOVA with Tukey’s post hoc tests). The same blot was reprobed with anti-STAT3. Expression controls for STAT3 and b-actin from total cell
lysates are also shown from an independent blot. Complete blot images are shown in Supplementary Fig. 3P–S. (E and G) SOD1G93A induced
activation of Vim, a target of STAT3, is significantly reduced in SOD/OXR1 mice at Days 90 and 135. (A–C and E–G) Values are mean  SEM
(n = 3–5 per genotype; *P5 0.05, **P5 0.01, ***P5 0.001, one-way ANOVA with Tukey’s post hoc tests). IP = immunoprecipitation;
WB = western blot.
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Lobsiger et al., 2007; Lee et al., 2013). While deletion of
C1q or C3, a protein central to both the classic and alter-
native complement pathway, does not affect onset of dis-
ease or survival, treatment with a selective C5aR antagonist
or loss of C5a receptor CD88 extends survival of mutant
SOD1 mice by 6% (Woodruff et al., 2008, 2014;
Lobsiger et al., 2013). In addition, we found that neuronal
OXR1 overexpression delays activation of STAT3 (Fig. 7).
In response to proinflammatory cytokines, STAT3, a tran-
scription factor, becomes activated, translocates to the nu-
cleus, and induces expression of additional immune
response genes, and activation of STAT3 has been observed
in motor neurons and glia cells in the spinal cord of ALS
patients and SOD1G93A mice (Shibata et al., 2009, 2010).
Moreover, we showed that induction of downstream tar-
gets of STAT3, such as Vim and Serpina3n, is similarly
reduced by neuronal OXR1 overexpression (Fig. 7).
Vimentin is an intermediate filament that forms inclusions
in mutant SOD1 motor neurons, an early pathological hall-
mark of ALS (Olsen et al., 2001; Yoshihara et al., 2002;
Perrin et al., 2005; Ferraiuolo et al., 2007). Similarly,
ERPINA3N accumulates along these neurofilamentous con-
glomerates, and the imbalance of serine proteases and their
respective inhibitors during oxidative injury may contribute
to the formation of ALS motor neuron inclusions (Chou
et al., 1998). Together, this evidence suggest that OXR1
functions upstream of multiple neuroinflammatory path-
ways during ALS pathogenesis, and that addressing mul-
tiple pathogenic mechanisms may be required to improve
survival due to compensatory pathways.
Cross-talk between neuroinflammation and oxidative
stress during ALS pathogenesis has been previously
hypothesized (Barber and Shaw, 2010). Damaged motor
neurons release reactive oxygen species, inducing oxidation
and reducing glutamate uptake in neighbouring astrocytes,
which subsequently leads to a cyclical process by which
increased extracellular glutamate levels and excitotoxicity
further damage motor neurons (Barber and Shaw, 2010).
Reactive oxygen species activate glial cells, which can sub-
sequently generate more reactive oxygen species, reactive
nitrogen species, and proinflammatory mediators, and
thereby activating more glial cells, all of which lead to
further motor neuron injury (Barber and Shaw, 2010).
Furthermore, mutant SOD1 in microglia disrupts regulation
of NADPH oxidase activity through persistent activation of
RAC1, resulting in prolonged production of reactive
oxygen species, which promote motor neuron apoptosis
(Harraz et al., 2008; Marchetto et al., 2008). While exact
mechanisms by which OXR1 regulates the immune re-
sponse remain elusive, OXR1 protects against oxidative
stress-induced apoptosis (Oliver et al., 2011), and loss of
OXR1 results in astrogliosis and microgliosis in the cere-
bellum and spinal cord (Supplementary Fig. 5). Therefore,
we hypothesize that OXR1 mediates cross-talk between
injured neurons and toxic mutant SOD1 microglia and
astrocytes by (i) conferring protection against increasing
intracellular levels of reactive oxygen species, reducing the
release of reactive oxygen species from damaged neurons,
and thereby decreasing glial cell activation; and (ii) confer-
ring protection against extracellular levels of reactive
oxygen species released by activated glia, which subse-
quently further extends survival of motor neurons, and
delays activation of additional glia.
Our previous data demonstrating OXR1 overexpression
in end-stage ALS spinal cord biopsies (Oliver et al., 2011)
suggest that the CNS is able to induce expression of the
protein as part of a stress response. This conclusion is in-
line with the initial studies of OXR1 that demonstrated
induction of the protein under heat or oxidative stress
(Volkert et al., 2000; Elliott and Volkert, 2004; Oliver
et al., 2011), in addition to in vivo studies in which
Oxr1 expression is induced under hypoxia in the mouse
retina (Natoli et al., 2008). Conversely, there are several
lines of evidence that the loss or reduction of OXR1 is
detrimental to the CNS in vivo; not only in the mouse
(Oliver et al., 2011), but also in the fly (Fischer et al.,
2001) and nematode worm (Sanada et al., 2014). Most
recently, OXR1 knockdown studies have suggested that
OXR1 modulates antioxidant pathways via the cyclin-
dependent kinase inhibitor 1A (p21) protein and nuclear
factor (erthyroid-derived 2)-like 2 (Nrf2, now known as
NFE2L2) (Yang et al., 2014), although the molecular
mechanisms are still unknown. Indeed, the OXR1 gene
does not seem to contain a positionally conserved antioxi-
dant response element (ARE), suggesting that OXR1 acts
upstream of Nrf2-related pathways (Wang et al., 2007). In
summary, it is clear that the levels of OXR1 are critical for
neuronal survival, and it will be important in the future to
examine the role of this protein within the antioxidant de-
fence and immune response pathways.
Finally, a meta-analysis of therapeutic strategies found
that drugs targeting inflammation prior to onset of symp-
toms and antioxidant pathways at symptom onset are most
effective in prolonging survival in mutant SOD1 mice
(Benatar, 2007). Here, we found that overexpression of
antioxidant OXR1 in neurons before onset of symptoms
modifies SOD1-mediated ALS and delays inflammatory
response, and presented evidence that a novel neuronal
antioxidant modulates the cross-talk between neuroinflam-
mation and oxidative stress during neurodegenerative
pathogenesis. Moreover, neuronal OXR1 overexpression
in vivo has no overt adverse effects (Fig. 1 and
Supplementary Fig. 2), and does not detrimentally alter
the spinal cord transcriptome (Supplementary Table 2).
Taken together, we demonstrated the potential for OXR1
to serve as a therapeutic target for ALS patients.
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